[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial
Sinopex's stock price is showing strong performance in early trading. The news of successfully completing clinical trials for the blood filter (dialysis) used in artificial kidneys for the first time in Korea is believed to have driven the stock price up.
As of 9:10 AM on the 7th, Sinopex is trading at 5,410 KRW, up 11.32% (550 KRW) compared to the previous session.
Sinopex announced through a press release that the patient-use clinical trial conducted on 50 hemodialysis patients at five major hospitals in Korea was successfully completed last week. This is the first official clinical trial conducted with a domestically produced blood dialysis filter for artificial kidneys, marking 59 years since hemodialysis began in Korea.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Currently, blood filters for artificial kidneys are entirely imported under duty-free conditions, but Sinopex has succeeded in domestic production and obtained product approval from the Ministry of Food and Drug Safety in March last year.
![[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial](http://www.asiae.co.kr/news/img_view.htm?img=2025030509433154739_1741135411.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
